Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration. [electronic resource]
Producer: 20131106Description: 1641-8 p. digitalISSN:- 1549-4713
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors -- therapeutic use
- Antibodies, Monoclonal, Humanized -- therapeutic use
- Bevacizumab
- Cohort Studies
- Complement C3b Inactivator Proteins -- genetics
- Complement Factor H -- genetics
- Complement System Proteins -- genetics
- Female
- Genotype
- High-Temperature Requirement A Serine Peptidase 1
- Humans
- Male
- Middle Aged
- Pharmacogenetics
- Polymorphism, Single Nucleotide
- Prospective Studies
- Proteins -- genetics
- Ranibizumab
- Retreatment
- Serine Endopeptidases -- genetics
- Treatment Outcome
- Vascular Endothelial Growth Factor A -- antagonists & inhibitors
- Visual Acuity -- physiology
- Wet Macular Degeneration -- drug therapy
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.